Marathon Trading Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Marathon Trading Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-37,400	Closed	-$577K	–	284
2018 Q4	$577K	Buy	+37,400	New	+$767K	0.03%	163
2016 Q4	–	Sell	-7,478	Closed	-$344K	–	169
2016 Q3	$344K	Buy	7,478 +700	+10%	+$36.5K	0.05%	97
2016 Q2	$340K	Hold	6,778	–	–	0.06%	99
2016 Q1	$363K	Sell	6,778 -1,000	-13%	-$58.7K	0.07%	105
2015 Q4	$511K	Sell	7,778 -800	-9%	-$49.4K	0.04%	171
2015 Q3	$484K	Sell	8,578 -21,200	-71%	-$1.37M	0.03%	228
2015 Q2	$1.76M	Buy	+29,778	New	+$1.84M	0.07%	172
2015 Q1	–	Sell	-47,800	Closed	-$2.78M	–	598
2014 Q4	$2.75M	Buy	+47,800	New	+$2.66M	0.04%	232

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marathon Trading Investment Management's TEVA Position: Q1 2019 in Review

Marathon Trading Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 37,400 shares — an estimated $577K sold.

Marathon Trading Investment Management first reported a position in TEVA in Q4 2014 and held it in 8 quarters. The position peaked at $2.75M in Q4 2014. 522 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

Marathon Trading Investment Management reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Marathon Trading Investment Management sold 37,400 Teva Pharmaceuticals shares in Q1 2019, an estimated $577K.
Marathon Trading Investment Management first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 8 quarters.
Marathon Trading Investment Management's Teva Pharmaceuticals position peaked at $2.75M in Q4 2014.
522 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Marathon Trading Investment Management's 13F filing for Q1 2019, filed 14 May 2019.